$JMTM
James Maritime Holdings Inc.

2024 Q4 Form 10-Q Financial Statement

#000109690624002113 Filed on November 14, 2024

View on sec.gov

Income Statement

Concept 2024 Q4 2024 Q3 2023 Q3
Revenue $989.5K $2.383M
YoY Change -58.48% -40.69%
Cost Of Revenue $975.1K $1.044M
YoY Change -6.59% -67.05%
Gross Profit $14.35K $1.339M
YoY Change -98.93% 57.61%
Gross Profit Margin 1.45% 56.19%
Selling, General & Admin $3.034M $1.176M
YoY Change 157.89% -52.88%
% of Gross Profit 21145.99% 87.86%
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization $10.34K
YoY Change
% of Gross Profit 0.77%
Operating Expenses $3.034M $1.176M
YoY Change 157.89% -52.88%
Operating Profit -$3.019M $162.5K
YoY Change -1957.72% -106.51%
Interest Expense $430.9K
YoY Change -43.78%
% of Operating Profit 265.12%
Other Income/Expense, Net -$249.9K -$430.9K
YoY Change -42.0% -117.68%
Pretax Income -$268.4K
YoY Change
Income Tax
% Of Pretax Income
Net Earnings -$3.269M -$268.4K
YoY Change 1118.22% -133.98%
Net Earnings / Revenue -330.41% -11.26%
Basic Earnings Per Share -$0.37 -$0.03
Diluted Earnings Per Share -$0.03
COMMON SHARES
Basic Shares Outstanding 9.064M shares 8.741M shares 9.064M shares
Diluted Shares Outstanding 9.064M shares

Balance Sheet

Concept 2024 Q4 2024 Q3 2023 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $21.76K
YoY Change
Cash & Equivalents $82.53K $21.76K
Short-Term Investments
Other Short-Term Assets $31.94K
YoY Change
Inventory
Prepaid Expenses
Receivables $170.5K $781.6K
Other Receivables $0.00
Total Short-Term Assets $271.8K $835.2K
YoY Change -67.46%
LONG-TERM ASSETS
Property, Plant & Equipment $104.7K $169.5K
YoY Change -38.22% -15.08%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $0.00
YoY Change
Total Long-Term Assets $2.481M $2.939M
YoY Change -15.59%
TOTAL ASSETS
Total Short-Term Assets $271.8K $835.2K
Total Long-Term Assets $2.481M $2.939M
Total Assets $2.753M $3.775M
YoY Change -27.07%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $903.3K $837.9K
YoY Change 7.8%
Accrued Expenses $668.6K
YoY Change
Deferred Revenue
YoY Change
Short-Term Debt $0.00
YoY Change
Long-Term Debt Due $1.465M
YoY Change
Total Short-Term Liabilities $3.365M $3.362M
YoY Change 0.1%
LONG-TERM LIABILITIES
Long-Term Debt $178.1K
YoY Change
Other Long-Term Liabilities $306.9K
YoY Change
Total Long-Term Liabilities $300.3K $485.0K
YoY Change -38.09%
TOTAL LIABILITIES
Total Short-Term Liabilities $3.365M $3.362M
Total Long-Term Liabilities $300.3K $485.0K
Total Liabilities $3.666M $3.847M
YoY Change -4.72%
SHAREHOLDERS EQUITY
Retained Earnings -$18.63M -$13.93M
YoY Change 33.72%
Common Stock $9.051K $9.064K
YoY Change -0.14%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$912.8K $113.8K
YoY Change
Total Liabilities & Shareholders Equity $2.753M $3.775M
YoY Change -27.07%

Cashflow Statement

Concept 2024 Q4 2024 Q3 2023 Q3
OPERATING ACTIVITIES
Net Income -$3.269M -$268.4K
YoY Change 1118.22% -133.98%
Depreciation, Depletion And Amortization $10.34K
YoY Change
Cash From Operating Activities -$106.4K
YoY Change
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 25.35K
YoY Change
NET CHANGE
Cash From Operating Activities -106.4K
Cash From Investing Activities
Cash From Financing Activities 25.35K
Net Change In Cash -81.08K
YoY Change
FREE CASH FLOW
Cash From Operating Activities -$106.4K
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2024Q3 us-gaap Assets Current
AssetsCurrent
271813 usd
CY2023Q4 us-gaap Assets Current
AssetsCurrent
808387 usd
CY2024Q3 jmtm Due From Related Parties Amount Noncurrent
DueFromRelatedPartiesAmountNoncurrent
7400 usd
CY2023Q4 jmtm Due From Related Parties Amount Noncurrent
DueFromRelatedPartiesAmountNoncurrent
7400 usd
CY2024Q3 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
2088274 usd
CY2023Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
2088274 usd
CY2024Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
104703 usd
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
159142 usd
CY2024Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
280720 usd
CY2023Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
346986 usd
CY2023Q4 us-gaap Loans Payable Current
LoansPayableCurrent
760842 usd
CY2024Q3 us-gaap Derivative Liabilities
DerivativeLiabilities
366528 usd
CY2023Q4 us-gaap Derivative Liabilities
DerivativeLiabilities
175045 usd
CY2024Q3 jmtm Operating Lease Liability Non Current
OperatingLeaseLiabilityNonCurrent
77178 usd
CY2023Q4 jmtm Operating Lease Liability Non Current
OperatingLeaseLiabilityNonCurrent
81805 usd
CY2024Q3 us-gaap Liabilities Current
LiabilitiesCurrent
3365407 usd
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
3266811 usd
CY2024Q3 jmtm Notes Payable Net
NotesPayableNet
0 usd
CY2023Q4 jmtm Notes Payable Net
NotesPayableNet
110287 usd
CY2024Q3 us-gaap Loans Payable
LoansPayable
67800 usd
CY2023Q4 us-gaap Loans Payable
LoansPayable
67800 usd
CY2024Q3 jmtm Long Term Operating Lease Liability
LongTermOperatingLeaseLiability
232464 usd
CY2023Q4 jmtm Long Term Operating Lease Liability
LongTermOperatingLeaseLiability
288413 usd
CY2024Q3 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
300264 usd
CY2023Q4 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
466500 usd
CY2024Q3 us-gaap Liabilities
Liabilities
3665671 usd
CY2023Q4 us-gaap Liabilities
Liabilities
3733311 usd
CY2024Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2024Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
90000000 shares
CY2024Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
9051429 shares
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
9064129 shares
CY2024Q3 us-gaap Common Stock Value
CommonStockValue
9051 usd
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
9064 usd
CY2024Q3 us-gaap Common Stock Share Subscribed But Unissued Subscriptions Receivable
CommonStockShareSubscribedButUnissuedSubscriptionsReceivable
0 usd
CY2024Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
17892502 usd
CY2023Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-186196 usd
CY2024Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
2752910 usd
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
3410189 usd
us-gaap Interest And Debt Expense
InterestAndDebtExpense
39052 usd
us-gaap Interest And Debt Expense
InterestAndDebtExpense
0 usd
us-gaap Share Based Compensation
ShareBasedCompensation
378900 usd
us-gaap Other Noncash Expense
OtherNoncashExpense
23421 usd
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-510580 usd
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
0 usd
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-23925 usd
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-17184 usd
us-gaap Increase Decrease In Due To Related Parties
IncreaseDecreaseInDueToRelatedParties
0 usd
us-gaap Increase Decrease In Due To Related Parties
IncreaseDecreaseInDueToRelatedParties
71975 usd
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
230460 usd
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
438123 usd
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
0 usd
us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
610478 usd
us-gaap Proceeds From Notes Payable
ProceedsFromNotesPayable
679200 usd
jmtm Repayment Of Loans Related Party
RepaymentOfLoansRelatedParty
0 usd
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
0 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-14039 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
67569 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
36983 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-433698 usd
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
45551 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
455453 usd
CY2024Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
82534 usd
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
21755 usd
us-gaap Interest Paid Net
InterestPaidNet
135032 usd
us-gaap Interest Paid Net
InterestPaidNet
0 usd
us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
0 usd
us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
0 usd
us-gaap Nature Of Operations
NatureOfOperations
<p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong><span style="text-decoration:underline">Note 1 - Organization and Nature of Operations</span></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Organization </strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The accompanying consolidated financial statements include the accounts of Sentinel Holdings, LLC (f/k/a James Maritime Holdings Inc. (“James Maritime”)) and its majority-owned subsidiaries, Gladiator Solutions Inc. (“Gladiator”), and United Security Specialists Inc. (“USS”) (collectively the “we”, “us”, “our”,  or the “Company”). We were incorporated in the State of Nevada on January 23, 2015.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Effective July 17, 2024 the Company effectuated a name change from James Maritime Holdings, Inc. to Sentinel Holdings Ltd. The name change was conducted in order to better reflect the current business activities of the Company and provide better transparency to the markets and our shareholders. The company is currently awaiting approval from FINRA regarding this name change.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Nature of Operations </strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Our lines of business consist of the following:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Gladiator </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Produces revenues through the distribution of personal protective products, primarily through mail-in orders to customers or via e-commerce sales generated through their website. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">USS</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Provides professional security personnel enhanced by smartphone-based security applications.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Basis of Presentation</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The accompanying unaudited consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America for interim financial statements (“U.S. GAAP”) and with the instructions to Form 10-Q and Article 8 of Regulation S-X of the United States Securities and Exchange Commission (“SEC”). Accordingly, they do not contain all information and footnotes required by accounting principles generally accepted in the United States of America for annual financial statements.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">In the opinion of the Company’s management, the accompanying unaudited consolidated financial statements contain all of the adjustments necessary (consisting only of normal recurring accruals) to present the financial position of the Company as of September 30, 2024 and the results of operations and cash flows for the periods presented. The results of operations for the three and nine months ended September 30, 2024 are not necessarily indicative of the operating results for the full fiscal year or any future period.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">These unaudited consolidated financial statements should be read in conjunction with the financial statements and related notes thereto included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2023, filed with the United States Securities and Exchange Commission on June 4, 2024.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Management acknowledges its responsibility for the preparation of the accompanying unaudited consolidated financial statements which reflect all adjustments, consisting of normal recurring adjustments, considered necessary in its opinion for a fair statement of its consolidated financial position and the consolidated results of its operations for the periods presented.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Liquidity and Going Concern</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">As reflected in the accompanying consolidated financial statements, for the nine months ended September 30, 2024, the Company had:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td style="width:4%;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">·</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Net loss of $4,712,641; and</p></td></tr><tr style="height:15px"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span style="font-family:symbol">·</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Net cash provided by operations was $51,022</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;"> </p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p></td></tr><tr style="height:15px"><td colspan="2" style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Additionally, at September 30, 2024, the Company had:</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;"> </p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p></td></tr><tr style="height:15px"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span style="font-family:symbol">·</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Accumulated deficit of $18,628,568</p></td></tr><tr style="height:15px"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span style="font-family:symbol">·</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Stockholders’ deficit of $912,761; and</p></td></tr><tr style="height:15px"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span style="font-family:symbol">·</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Working capital deficit of $3,093,594</p></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">  </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Company anticipates that it will need to raise additional capital immediately in order to continue to fund its operations. The Company has relied on related parties for debt based funding of its operations. There is no assurance that the Company will be able to obtain funds on commercially acceptable terms, if at all. There is also no assurance that the amount of funds the Company might raise will enable the Company to complete its initiatives or attain profitable operations. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Company’s operating needs include the planned costs to operate its business, including amounts required to fund working capital and capital expenditures. The Company’s future capital requirements and the adequacy of its available funds will depend on many factors, including the Company’s ability to successfully expand to new markets, competition, and the need to enter into collaborations with other companies or acquire other companies to enhance or complement its product and service offerings. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">There can be no assurances that financing will be available on terms which are favorable, or at all. If the Company is unable to raise additional funding to meet its working capital needs in the future, it will be forced to delay, reduce, or cease its operations.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">We manage liquidity risk by reviewing, on an ongoing basis, our sources of liquidity and capital requirements. The Company had cash on hand of $82,534 at September 30, 2024. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Company has historically incurred significant losses since inception and has not demonstrated an ability to generate sufficient revenues from the sales of its products and services to achieve profitable operations. In making this assessment we performed a comprehensive analysis of our current circumstances including: our financial position, our cash flows and cash usage forecasts for the twelve months ended June 30, 2025, and our current capital structure including equity-based instruments and our obligations and debts.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">These factors create substantial doubt about the Company’s ability to continue as a going concern within the twelve-month period subsequent to the date that these financial statements are issued. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The consolidated financial statements do not include any adjustments that might be necessary if the Company is unable to continue as a going concern. Accordingly, the financial statements have been prepared on a basis that assumes the Company will continue as a going concern and which contemplates the realization of assets and satisfaction of liabilities and commitments in the ordinary course of business.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span style="text-decoration:underline">Management’s strategic plans include the following:  </span></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td style="width:4%;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">·</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Expand into new and existing markets (commercial and residential),</p></td></tr><tr style="height:15px"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span style="font-family:symbol">·</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Obtain additional debt and/or equity based financing,</p></td></tr><tr style="height:15px"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span style="font-family:symbol">·</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Collaborations with other operating businesses for strategic opportunities; and</p></td></tr><tr style="height:15px"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span style="font-family:symbol">·</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Acquire other businesses to enhance or complement our current business model while accelerating our growth.</p></td></tr></tbody></table>
jmtm Net Loss
NetLoss
-4712641 usd
us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
51022 usd
CY2024Q3 jmtm Accumulated Deficit
AccumulatedDeficit
-18628568 usd
CY2024Q3 jmtm Stockholders Equity Deficit Amount
StockholdersEquityDeficitAmount
-912761 usd
CY2024Q3 jmtm Working Capital Deficit
WorkingCapitalDeficit
-3093594 usd
CY2024Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
82534 usd
CY2024Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
903275 usd
CY2024Q3 us-gaap Accrued Bonuses Current
AccruedBonusesCurrent
997093 usd
CY2021Q1 us-gaap Debt Instrument Interest Rate Stated Percentage
DebtInstrumentInterestRateStatedPercentage
0.0375 pure
CY2024Q3 jmtm Accrued Interest Expense
AccruedInterestExpense
9190 usd
CY2023Q4 jmtm Accrued Interest Expense
AccruedInterestExpense
7204 usd
us-gaap Derivative Term Of Contract
DerivativeTermOfContract
P1Y
CY2023 us-gaap Derivative Term Of Contract
DerivativeTermOfContract
P1Y
jmtm Derivative Liabilities Expected Voladility
DerivativeLiabilitiesExpectedVoladility
0.62 pure
CY2023 jmtm Derivative Liabilities Expected Voladility
DerivativeLiabilitiesExpectedVoladility
0.41 pure
jmtm Derivative Expected Dividends
DerivativeExpectedDividends
0.0000 pure
CY2023 jmtm Derivative Expected Dividends
DerivativeExpectedDividends
0.0000 pure
us-gaap Debt Instrument Interest Rate During Period
DebtInstrumentInterestRateDuringPeriod
0.0509 pure
CY2023 us-gaap Debt Instrument Interest Rate During Period
DebtInstrumentInterestRateDuringPeriod
0.0479 pure
CY2022Q4 us-gaap Derivative Liabilities
DerivativeLiabilities
331399 usd
CY2023 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-156354 usd
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
191483 usd
CY2024Q3 jmtm Derivative Liabilities Ending Balance
DerivativeLiabilitiesEndingBalance
366528 usd
us-gaap Increase Decrease In Derivative Liabilities
IncreaseDecreaseInDerivativeLiabilities
-191483 usd
us-gaap Increase Decrease In Derivative Liabilities
IncreaseDecreaseInDerivativeLiabilities
156354 usd
jmtm Derivative Expense
DerivativeExpense
0 usd
jmtm Derivative Expense
DerivativeExpense
0 usd
jmtm Lessee Operating Lease Term
LesseeOperatingLeaseTerm
P12M
jmtm Lease Term Contract
LeaseTermContract
Company entered into an office lease for its administrative operations, (the “Saratoga lease”). The Saratoga lease is for a 48.5-month term, with an original expiration date of July 31, 2024
jmtm Lease Initial Payment
LeaseInitialPayment
8819 usd
jmtm Straight Line Rent Installment
StraightLineRentInstallment
9522 usd
CY2023Q1 jmtm Lease Term Contract
LeaseTermContract
Company entered a new lease for its headquarters office, (the “Suite 200 Lease”) for a 60 month lease with an expiration date of January 31, 2028
CY2023Q1 jmtm Lease Initial Payment
LeaseInitialPayment
7943 usd
CY2024Q3 jmtm Operating Lease Right Of Use Asset Non Current
OperatingLeaseRightOfUseAssetNonCurrent
280720 usd
CY2023Q4 jmtm Operating Lease Right Of Use Asset Non Current
OperatingLeaseRightOfUseAssetNonCurrent
168339 usd
CY2024Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
309642 usd
CY2023Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
183353 usd
jmtm Operating Lease Weighted Average Remaining Lease Term
OperatingLeaseWeightedAverageRemainingLeaseTerm
P3Y4M2D
CY2023 jmtm Operating Lease Weighted Average Remaining Lease Term
OperatingLeaseWeightedAverageRemainingLeaseTerm
P1Y6M29D
CY2024Q3 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.0800 pure
CY2023Q4 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.0800 pure
us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
63162 usd
us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
42108 usd
jmtm Lease Liability Expense In Connection With Obligation Repayment
LeaseLiabilityExpenseInConnectionWithObligationRepayment
20368 usd
jmtm Lease Liability Expense In Connection With Obligation Repayment
LeaseLiabilityExpenseInConnectionWithObligationRepayment
14833 usd
us-gaap Operating Lease Cost
OperatingLeaseCost
83530 usd
us-gaap Operating Lease Cost
OperatingLeaseCost
56941 usd
jmtm Operating Cash Outflows From Operating Lease
OperatingCashOutflowsFromOperatingLease
73391 usd
jmtm Operating Cash Outflows From Operating Lease
OperatingCashOutflowsFromOperatingLease
47896 usd
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
0 usd
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
421080 usd
CY2024Q3 us-gaap Lessee Operating Lease Liability Payments Due In Rolling Year Two
LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearTwo
103661 usd
CY2024Q3 us-gaap Lessee Operating Lease Liability Payments Due In Rolling Year Three
LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearThree
107020 usd
CY2024Q3 us-gaap Lessee Operating Lease Liability Payments Due In Rolling Year Four
LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFour
110228 usd
CY2024Q3 us-gaap Lessee Operating Lease Liability Payments Due In Rolling Year Five
LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFive
9208 usd
CY2024Q3 jmtm Operating Lease Undiscounted Cash Flows
OperatingLeaseUndiscountedCashFlows
354660 usd
CY2024Q3 jmtm Amount Representing Interest
AmountRepresentingInterest
45018 usd
CY2024Q3 jmtm Present Value Of Operating Lease Liability
PresentValueOfOperatingLeaseLiability
309642 usd
dei Entity Central Index Key
EntityCentralIndexKey
0000889353
dei Amendment Flag
AmendmentFlag
false
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2024
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
90000000 shares
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
9064129 shares
CY2024Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
9051429 shares
CY2023Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
0 usd
CY2023Q4 jmtm Derivative Liabilities Ending Balance
DerivativeLiabilitiesEndingBalance
175045 usd
CY2022Q4 jmtm Share Based Compensation Arrangement By Share Based Payment Award Non Vested Equity Instruments Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonVestedEquityInstrumentsOutstandingNumber
0 shares
CY2023Q4 jmtm Share Based Compensation Arrangement By Share Based Payment Award Non Vested Equity Instruments Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonVestedEquityInstrumentsOutstandingNumber
0 shares
CY2023 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Granted
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted
0 shares
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercised
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised
0 shares
CY2023 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercised
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised
0 shares
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Expirations
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations
0 shares
CY2023 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Expirations
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations
0 shares
CY2024Q3 jmtm Share Based Compensation Arrangement By Share Based Payment Award Non Vested Equity Instruments Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonVestedEquityInstrumentsOutstandingNumber
0 shares
CY2022Q4 jmtm Share Based Compensation Arrangement By Share Based Payment Award Options Unvested Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedWeightedAverageExercisePrice
0
CY2023Q4 jmtm Share Based Compensation Arrangement By Share Based Payment Award Options Unvested Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedWeightedAverageExercisePrice
0
CY2023 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
0.00
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
0.00
CY2023 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
0.00
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
0.00
CY2023 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
0.00
CY2024Q3 jmtm Share Based Compensation Arrangement By Share Based Payment Award Options Unvested Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedWeightedAverageExercisePrice
0
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2024-09-30
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
000-55805
dei Entity Registrant Name
EntityRegistrantName
JAMES MARITIME HOLDINGS INC.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
NV
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
95-4363944
dei Entity Address Address Line1
EntityAddressAddressLine1
9360 South 300 West
dei Entity Address Address Line2
EntityAddressAddressLine2
#101
dei Entity Address City Or Town
EntityAddressCityOrTown
Sandy
dei Entity Address State Or Province
EntityAddressStateOrProvince
UT
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
84070
dei City Area Code
CityAreaCode
801
dei Local Phone Number
LocalPhoneNumber
706-9429
dei Entity Current Reporting Status
EntityCurrentReportingStatus
No
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2024Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
9064129 shares
CY2024Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
82534 usd
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
45551 usd
CY2024Q3 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
170480 usd
CY2023Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
720112 usd
CY2024Q3 us-gaap Prepaid Expense And Other Assets
PrepaidExpenseAndOtherAssets
18799 usd
CY2023Q4 us-gaap Prepaid Expense And Other Assets
PrepaidExpenseAndOtherAssets
42724 usd
CY2024Q3 us-gaap Assets
Assets
2752910 usd
CY2023Q4 us-gaap Assets
Assets
3410189 usd
CY2024Q3 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
1900368 usd
CY2023Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
1669908 usd
CY2024Q3 jmtm Due To Related Party Current
DueToRelatedPartyCurrent
0 usd
CY2023Q4 jmtm Due To Related Party Current
DueToRelatedPartyCurrent
7960 usd
CY2024Q3 us-gaap Notes Payable Current
NotesPayableCurrent
443400 usd
CY2023Q4 us-gaap Notes Payable Current
NotesPayableCurrent
536251 usd
CY2024Q3 us-gaap Convertible Debt Current
ConvertibleDebtCurrent
35000 usd
CY2023Q4 us-gaap Convertible Debt Current
ConvertibleDebtCurrent
35000 usd
CY2024Q3 us-gaap Loans Payable Current
LoansPayableCurrent
542933 usd
CY2023Q4 us-gaap Common Stock Share Subscribed But Unissued Subscriptions Receivable
CommonStockShareSubscribedButUnissuedSubscriptionsReceivable
0 usd
CY2023Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
13769537 usd
CY2024Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-18628568 usd
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-13915927 usd
CY2024Q3 jmtm Deficit Attributable To Stockholders Of James Maritime Holdings Inc
DeficitAttributableToStockholdersOfJamesMaritimeHoldingsInc
-726565 usd
CY2023Q4 jmtm Deficit Attributable To Stockholders Of James Maritime Holdings Inc
DeficitAttributableToStockholdersOfJamesMaritimeHoldingsInc
-136926 usd
CY2024Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-186196 usd
CY2024Q3 us-gaap Stockholders Equity
StockholdersEquity
-912761 usd
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
-323122 usd
CY2024Q3 us-gaap Revenues
Revenues
989486 usd
CY2023Q3 us-gaap Revenues
Revenues
2382896 usd
us-gaap Revenues
Revenues
4025410 usd
us-gaap Revenues
Revenues
6915105 usd
CY2024Q3 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
975139 usd
CY2023Q3 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
1043945 usd
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
3411620 usd
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
4995598 usd
CY2024Q3 us-gaap Gross Profit
GrossProfit
14347 usd
CY2023Q3 us-gaap Gross Profit
GrossProfit
1338951 usd
us-gaap Gross Profit
GrossProfit
613790 usd
us-gaap Gross Profit
GrossProfit
1919507 usd
CY2024Q3 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
3033815 usd
CY2023Q3 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
1176414 usd
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
5440974 usd
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
3925755 usd
CY2024Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-3019468 usd
CY2023Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
162537 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-4827184 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-2006248 usd
CY2024Q3 us-gaap Interest Expense Nonoperating
InterestExpenseNonoperating
199912 usd
CY2023Q3 us-gaap Interest Expense Nonoperating
InterestExpenseNonoperating
430910 usd
us-gaap Interest Expense Nonoperating
InterestExpenseNonoperating
775588 usd
us-gaap Interest Expense Nonoperating
InterestExpenseNonoperating
757807 usd
CY2024Q3 us-gaap Financing Interest Expense
FinancingInterestExpense
0 usd
CY2023Q3 us-gaap Financing Interest Expense
FinancingInterestExpense
0 usd
us-gaap Financing Interest Expense
FinancingInterestExpense
0 usd
us-gaap Financing Interest Expense
FinancingInterestExpense
26607 usd
CY2024Q3 us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
-49812 usd
CY2023Q3 us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
0 usd
us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
-191483 usd
us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
156354 usd
CY2024Q3 jmtm Paycheck Protection Program Forgiveness
PaycheckProtectionProgramForgiveness
0 usd
CY2023Q3 jmtm Paycheck Protection Program Forgiveness
PaycheckProtectionProgramForgiveness
0 usd
jmtm Paycheck Protection Program Forgiveness
PaycheckProtectionProgramForgiveness
1091374 usd
jmtm Paycheck Protection Program Forgiveness
PaycheckProtectionProgramForgiveness
0 usd
CY2024Q3 us-gaap Impairment Of Intangible Assets Finitelived
ImpairmentOfIntangibleAssetsFinitelived
0 usd
CY2023Q3 us-gaap Impairment Of Intangible Assets Finitelived
ImpairmentOfIntangibleAssetsFinitelived
0 usd
us-gaap Impairment Of Intangible Assets Finitelived
ImpairmentOfIntangibleAssetsFinitelived
0 usd
us-gaap Impairment Of Intangible Assets Finitelived
ImpairmentOfIntangibleAssetsFinitelived
0 usd
CY2024Q3 us-gaap Other Nonoperating Income
OtherNonoperatingIncome
-198 usd
CY2023Q3 us-gaap Other Nonoperating Income
OtherNonoperatingIncome
0 usd
us-gaap Other Nonoperating Income
OtherNonoperatingIncome
-9760 usd
us-gaap Other Nonoperating Income
OtherNonoperatingIncome
322 usd
CY2024Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-249922 usd
CY2023Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-430910 usd
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
114543 usd
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-627738 usd
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
-3269390 usd
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-268373 usd
us-gaap Net Income Loss
NetIncomeLoss
-4712641 usd
us-gaap Net Income Loss
NetIncomeLoss
-2633986 usd
CY2024Q3 us-gaap Income Loss Attributable To Noncontrolling Interest
IncomeLossAttributableToNoncontrollingInterest
0 usd
CY2023Q3 us-gaap Income Loss Attributable To Noncontrolling Interest
IncomeLossAttributableToNoncontrollingInterest
0 usd
us-gaap Income Loss Attributable To Noncontrolling Interest
IncomeLossAttributableToNoncontrollingInterest
0 usd
us-gaap Income Loss Attributable To Noncontrolling Interest
IncomeLossAttributableToNoncontrollingInterest
-157098 usd
CY2024Q3 us-gaap Income Loss Attributable To Parent
IncomeLossAttributableToParent
-3269390 usd
CY2023Q3 us-gaap Income Loss Attributable To Parent
IncomeLossAttributableToParent
-268373 usd
us-gaap Income Loss Attributable To Parent
IncomeLossAttributableToParent
-4712641 usd
us-gaap Income Loss Attributable To Parent
IncomeLossAttributableToParent
-2476888 usd
CY2024Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.37
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.03
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.53
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.27
CY2024Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
8939799 shares
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
9064129 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
8818430 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
9064129 shares
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
-323122 usd
CY2024Q1 jmtm Shares Cancelled Amount
SharesCancelledAmount
-867 usd
CY2024Q1 jmtm Shares Issued Amount
SharesIssuedAmount
369 usd
CY2024Q1 us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
0 usd
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
1352480 usd
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
1028860 usd
CY2024Q2 jmtm Stock And Warrants Issued During Period For Cash
StockAndWarrantsIssuedDuringPeriodForCash
75000 usd
CY2024Q2 jmtm Warrants Issued For Services Rendered
WarrantsIssuedForServicesRendered
1138500 usd
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
-2795731 usd
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
553371 usd
CY2024Q3 jmtm Stock And Warrants Issued During Period For Cash
StockAndWarrantsIssuedDuringPeriodForCash
410000 usd
CY2024Q3 jmtm Stock Issued For Services Amount
StockIssuedForServicesAmount
2500000 usd
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
-3269390 usd
CY2024Q3 us-gaap Stockholders Equity
StockholdersEquity
-912761 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
2182693 usd
CY2023Q1 jmtm Stock Issued For Services Amount
StockIssuedForServicesAmount
0 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-1192552 usd
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
990141 usd
CY2023Q2 jmtm Stock Issued For Services Amount
StockIssuedForServicesAmount
378900 usd
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-1173060 usd
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
195981 usd
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-268373 usd
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
-72393 usd
us-gaap Profit Loss
ProfitLoss
4712641 usd
us-gaap Profit Loss
ProfitLoss
2633986 usd
jmtm Loss On Impairment Of Goodwill And Intangibles
LossOnImpairmentOfGoodwillAndIntangibles
0 usd
jmtm Loss On Impairment Of Goodwill And Intangibles
LossOnImpairmentOfGoodwillAndIntangibles
911467 usd
us-gaap Depreciation And Amortization
DepreciationAndAmortization
31018 usd
us-gaap Depreciation And Amortization
DepreciationAndAmortization
1090523 usd
jmtm Amortization Of Operating Lease Right Of Use Asset
AmortizationOfOperatingLeaseRightOfUseAsset
66266 usd
jmtm Amortization Of Operating Lease Right Of Use Asset
AmortizationOfOperatingLeaseRightOfUseAsset
0 usd
us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
70032 usd
us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
37032 usd
jmtm Warrants Issued For Services Rendered
WarrantsIssuedForServicesRendered
1138500 usd
jmtm Warrants Issued For Services Rendered
WarrantsIssuedForServicesRendered
0 usd
us-gaap Share Based Compensation
ShareBasedCompensation
2499502 usd
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
59184 usd
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
196947 usd
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-400000 usd
jmtm Change In Fair Value Of Derivative Liability
ChangeInFairValueOfDerivativeLiability
-191483 usd
jmtm Change In Fair Value Of Derivative Liability
ChangeInFairValueOfDerivativeLiability
156354 usd
jmtm Operating Lease Liability During Period
OperatingLeaseLiabilityDuringPeriod
60576 usd
jmtm Operating Lease Liability During Period
OperatingLeaseLiabilityDuringPeriod
0 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
51022 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-501267 usd
us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
529044 usd
us-gaap Proceeds From Notes Payable
ProceedsFromNotesPayable
348874 usd
us-gaap Payments Of Loan Costs
PaymentsOfLoanCosts
310909 usd
us-gaap Payments Of Loan Costs
PaymentsOfLoanCosts
1153 usd
jmtm Repayment Of Loans Related Party
RepaymentOfLoansRelatedParty
7960 usd
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
485000 usd
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
0 usd
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
0 usd
us-gaap Use Of Estimates
UseOfEstimates
<p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Preparing financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements and revenues and expenses during the reported period. Actual results could differ from those estimates, and those estimates may be material. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Changes in estimates are recorded in the period in which they become known. The Company bases its estimates on historical experience and other assumptions, which include both quantitative and qualitative assessments that it believes to be reasonable under the circumstances. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Significant estimates during the nine months ended September 30, 2024 and 2023, respectively, include, allowance for doubtful accounts receivable,  valuation of loss contingencies, valuation of stock-based compensation, estimated useful lives related to property and equipment, impairment of intangible assets, implicit interest rate in right-of-use operating leases, uncertain tax positions, and the valuation allowance on deferred tax assets.</p>
CY2024Q3 us-gaap Cash Fdic Insured Amount
CashFDICInsuredAmount
250000 usd
CY2024Q3 us-gaap Accounts Receivable Gross
AccountsReceivableGross
170480 usd
CY2023Q4 us-gaap Accounts Receivable Gross
AccountsReceivableGross
720112 usd
CY2024Q3 us-gaap Allowance For Doubtful Accounts Receivable
AllowanceForDoubtfulAccountsReceivable
0 usd
CY2023Q4 us-gaap Allowance For Doubtful Accounts Receivable
AllowanceForDoubtfulAccountsReceivable
0 usd
CY2024Q3 us-gaap Accounts Receivable Net
AccountsReceivableNet
170480 usd
CY2023Q4 us-gaap Accounts Receivable Net
AccountsReceivableNet
720112 usd
us-gaap Interest And Debt Expense
InterestAndDebtExpense
39052 usd
us-gaap Interest And Debt Expense
InterestAndDebtExpense
0 usd
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Company has the following concentrations related to its accounts receivable greater than 10% of their respective totals:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="6" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>AR</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: 1px solid;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>Nine Months Ended September 30, </strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>Year Ended December 31,</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Customer </strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2024</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2023</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">A</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">67.73</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">%</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">27.94</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">%</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">B</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">0.00</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">%</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">30.85</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">%</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Total</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">67.73</td><td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;">%</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">58.79</td><td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;">%</td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">   </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> Company has the following concentrations related to its sales greater than 10% of their respective totals:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td style="BORDER-BOTTOM: 1px solid;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="6" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Nine Months Ended September 30, </strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Customer </strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2024</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2023</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">A</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">24.81</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">%</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">12.19</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">%</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">B</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">8.16</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">%</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">21.12</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">%</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Total</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">32.97</td><td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;">%</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">33.31</td><td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;">%</td></tr></tbody></table>
jmtm Concentration Risk Percentage Accounts Receivable
ConcentrationRiskPercentageAccountsReceivable
0.6773 pure
CY2023 jmtm Concentration Risk Percentage Accounts Receivable
ConcentrationRiskPercentageAccountsReceivable
0.5879 pure
jmtm Concentration Risk Percentage Sales
ConcentrationRiskPercentageSales
0.3297 pure
jmtm Concentration Risk Percentage Sales
ConcentrationRiskPercentageSales
0.3331 pure
CY2024Q3 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
0 usd
CY2024Q3 us-gaap Marketing And Advertising Expense
MarketingAndAdvertisingExpense
15778 usd
CY2023Q3 us-gaap Marketing And Advertising Expense
MarketingAndAdvertisingExpense
28444 usd
us-gaap Marketing And Advertising Expense
MarketingAndAdvertisingExpense
21049 usd
us-gaap Marketing And Advertising Expense
MarketingAndAdvertisingExpense
62332 usd
us-gaap Incremental Common Shares Attributable To Call Options And Warrants
IncrementalCommonSharesAttributableToCallOptionsAndWarrants
2450000 shares
CY2023 us-gaap Incremental Common Shares Attributable To Call Options And Warrants
IncrementalCommonSharesAttributableToCallOptionsAndWarrants
1000000 shares
CY2024Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
90000000 shares
CY2024Q3 jmtm Due From Shareholders
DueFromShareholders
100000 usd
us-gaap Depreciation
Depreciation
31018 usd
us-gaap Depreciation
Depreciation
1090523 usd
CY2024Q3 us-gaap Goodwill Impaired Accumulated Impairment Loss
GoodwillImpairedAccumulatedImpairmentLoss
0 usd
CY2023Q3 us-gaap Goodwill Impaired Accumulated Impairment Loss
GoodwillImpairedAccumulatedImpairmentLoss
911467 usd
CY2023Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1107173 usd
CY2023Q4 us-gaap Accrued Bonuses Current
AccruedBonusesCurrent
562735 usd
CY2024Q3 us-gaap Accounts Payable And Other Accrued Liabilities
AccountsPayableAndOtherAccruedLiabilities
1900368 usd
CY2023Q4 us-gaap Accounts Payable And Other Accrued Liabilities
AccountsPayableAndOtherAccruedLiabilities
1669908 usd
CY2021Q1 us-gaap Proceeds From Loans
ProceedsFromLoans
67900 usd
CY2023Q4 us-gaap Derivative Liabilities
DerivativeLiabilities
175045 usd
CY2024Q3 us-gaap Lessee Operating Lease Liability Payments Due Next Rolling Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextRollingTwelveMonths
24543 usd
CY2024Q3 jmtm Current Portion Of Operating Lease Liability
CurrentPortionOfOperatingLeaseLiability
77178 usd
CY2024Q3 jmtm Long Term Portion Of Operating Lease Liabilities
LongTermPortionOfOperatingLeaseLiabilities
232464 usd
CY2024Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
90000000 shares
CY2024Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
9051429 shares
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
9064129 shares
CY2024Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
us-gaap Preferred Stock Voting Rights
PreferredStockVotingRights
1 vote per share
CY2024Q3 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
17500 shares
CY2024Q3 us-gaap Sale Of Stock Price Per Share
SaleOfStockPricePerShare
1
CY2024Q3 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
17500 usd
CY2024Q3 jmtm Preferred Stock Issued Majority Shareholder
PreferredStockIssuedMajorityShareholder
50000 shares
CY2024Q3 jmtm Conversion Of Preferred Stock Into Common Stock
ConversionOfPreferredStockIntoCommonStock
50 shares
CY2024Q3 jmtm Equivalent Common Shares
EquivalentCommonShares
2500000 shares
CY2024Q3 us-gaap Sale Of Stock Price Per Share
SaleOfStockPricePerShare
1.00
CY2024Q3 us-gaap Treasury Stock Preferred Value
TreasuryStockPreferredValue
2500000 usd
jmtm Summaryoffairvalueofallwarrantsgranted Table Textblock
SummaryoffairvalueofallwarrantsgrantedTableTextblock
<table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"><tbody><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Expected term (years)</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2.73</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Expected volatility</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">52</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">%</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Expected dividends</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">0.00</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">%</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Risk free interest rate</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">4.60</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">%</td></tr></tbody></table>
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber
1000000 shares
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
3.50
CY2022 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P2Y6M25D
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
0 usd
CY2022Q4 jmtm Share Based Compensation Arrangement By Share Based Payment Award Vested Exercisable
ShareBasedCompensationArrangementByShareBasedPaymentAwardVestedExercisable
1000000 shares
CY2022Q4 jmtm Share Based Compensation Arrangement By Share Based Payment Award Options Weighted Average Exercise Price Vested And Exercisable
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageExercisePriceVestedAndExercisable
3.50
CY2022 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
P2Y6M25D
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
0 usd
CY2022Q4 jmtm Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Options Nonvested Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherOptionsNonvestedIntrinsicValue
0 usd
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber
1000000 shares
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
3.50
CY2023 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P1Y6M25D
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
2500000 usd
CY2023Q4 jmtm Share Based Compensation Arrangement By Share Based Payment Award Vested Exercisable
ShareBasedCompensationArrangementByShareBasedPaymentAwardVestedExercisable
1000000 shares
CY2023Q4 jmtm Share Based Compensation Arrangement By Share Based Payment Award Options Weighted Average Exercise Price Vested And Exercisable
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageExercisePriceVestedAndExercisable
3.50
CY2023 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
P1Y6M25D
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
2500000 usd
CY2023Q4 jmtm Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Options Nonvested Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherOptionsNonvestedIntrinsicValue
0 usd
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Granted
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted
1000000 shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
3.50
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber
2000000 shares
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
3.50
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P1Y6M
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
0 usd
CY2024Q3 jmtm Share Based Compensation Arrangement By Share Based Payment Award Vested Exercisable
ShareBasedCompensationArrangementByShareBasedPaymentAwardVestedExercisable
2000000 shares
CY2024Q3 jmtm Share Based Compensation Arrangement By Share Based Payment Award Options Weighted Average Exercise Price Vested And Exercisable
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageExercisePriceVestedAndExercisable
3.50
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
P1Y6M
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
0 usd
CY2024Q3 jmtm Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Options Nonvested Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherOptionsNonvestedIntrinsicValue
0 usd

Files In Submission

Name View Source Status
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
0001096906-24-002113-index-headers.html Edgar Link pending
0001096906-24-002113-index.html Edgar Link pending
0001096906-24-002113.txt Edgar Link pending
0001096906-24-002113-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
jmtm-20240930.xsd Edgar Link pending
jmtm_10q.htm Edgar Link pending
jmtm_ex311.htm Edgar Link pending
jmtm_ex312.htm Edgar Link pending
jmtm_ex321.htm Edgar Link pending
jmtm_ex322.htm Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
jmtm-20240930_cal.xml Edgar Link unprocessable
jmtm-20240930_lab.xml Edgar Link unprocessable
jmtm-20240930_pre.xml Edgar Link unprocessable
jmtm_10q_htm.xml Edgar Link completed
jmtm-20240930_def.xml Edgar Link unprocessable